Vaccine Manufacturing Technology and Services: World Market 2013-2023
Your guide to trends and revenue prospects for vaccine production
What's the outlook for producing vaccines? Visiongain's updated report gives you forecasted revenues to 2023. It explains trends, opportunities and prospects for those technologies.а
Our study lets you assess sales data at overall world market, submarket and national level. There you find the most promising and lucrative areas in the production of vaccines, helping your research and analyses.
There's rising demand for those products and services. In particular, outsourced vaccine manufacturing will expand from 2013 to 2023, with growing revenues.
Forecasts and other analyses to help you stay ahead in knowledge
In our work you find revenue forecasting to 2023, historical data, growth rates and market shares. Also, you see qualitative analysis (SWOT and STEP), business news, outlooks and developmental trends. You receive 70 tables, 46 charts and two research interviews.
You discover industry dynamics and growth potentials - the following sections show what you find in our new report.
Discover prospects for the world market and submarkets
Along with revenue prediction for the overall world market, you see forecasts to 2023 for these five submarkets:
Our work also breaks the main world forecast into leading geographical markets.
What prospects for leading regions and countries?
Developments worldwide will influence the market from 2013, especially production of vaccines in emerging countries. There exist many opportunities for pharma companies and contract manufacturing organisations (CMOs). See prospects for the industry.
You get individual forecasts to 2023 for eleven national markets, finding overall revenues:
What affects vaccine manufacturing from 2013?
Our report discusses issues and events affecting that industry and market from 2013 onwards:
Leading companies and 2015 market values
We predict that the world market for vaccines will reach $48bn in 2015, and expand further to 2023. Also, vaccine contract manufacturing will reach $0.62bn in 2015. That outsourcing segment holds great potential for investment, development and growth from 2013.
Preventive healthcare has rising importance. We review these leading producers:
Eight ways Vaccine Manufacturing Technology and Services: World Market 2013-2023 helps
In particular, then, our investigation gives you the following knowledge:
That work gives independent analysis. You receive business intelligence found only in our report, seeing where financial prospects are good.
With our study you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses and decisions, saving time and getting you recognition for insight.
Ordering now lets you discover commercial prospects to 2023
Visiongain's investigation is for everyone needing forward-looking analysis of the vaccines industry and market. You find data, trends and predictions. Please order our report now.
What's the outlook for producing vaccines? Visiongain's updated report gives you forecasted revenues to 2023. It explains trends, opportunities and prospects for those technologies.а
Our study lets you assess sales data at overall world market, submarket and national level. There you find the most promising and lucrative areas in the production of vaccines, helping your research and analyses.
There's rising demand for those products and services. In particular, outsourced vaccine manufacturing will expand from 2013 to 2023, with growing revenues.
Forecasts and other analyses to help you stay ahead in knowledge
In our work you find revenue forecasting to 2023, historical data, growth rates and market shares. Also, you see qualitative analysis (SWOT and STEP), business news, outlooks and developmental trends. You receive 70 tables, 46 charts and two research interviews.
You discover industry dynamics and growth potentials - the following sections show what you find in our new report.
Discover prospects for the world market and submarkets
Along with revenue prediction for the overall world market, you see forecasts to 2023 for these five submarkets:
- Paediatric vaccines
- Influenza vaccines
- Adult prophylactic vaccines
- Therapeutic vaccines
- Contract vaccine manufacturing.
Our work also breaks the main world forecast into leading geographical markets.
What prospects for leading regions and countries?
Developments worldwide will influence the market from 2013, especially production of vaccines in emerging countries. There exist many opportunities for pharma companies and contract manufacturing organisations (CMOs). See prospects for the industry.
You get individual forecasts to 2023 for eleven national markets, finding overall revenues:
- US
- Japan
- Germany, France, UK, Italy and Spain (EU5)
- Brazil, Russia, India and China (BRIC nations).
What affects vaccine manufacturing from 2013?
Our report discusses issues and events affecting that industry and market from 2013 onwards:
- Cell-based techniques - mammalian cell lines, avian-derived cells, plant-based processes and other methods
- Next-generation expression systems and vectors - increasing yields
- Recombinant DNA technologies
- Equipment, including single-use (disposable) bioreactors and prefilled syringes
- Product stability, lyophilisation and quality assurance programmes.
- Reasons, strategies and benefits for outsourcing production
- Services offered by CMOs
- Pandemic preparedness, bioterrorism, storage and distribution networks
- Pricing, regulation and governmental policy.
Leading companies and 2015 market values
We predict that the world market for vaccines will reach $48bn in 2015, and expand further to 2023. Also, vaccine contract manufacturing will reach $0.62bn in 2015. That outsourcing segment holds great potential for investment, development and growth from 2013.
Preventive healthcare has rising importance. We review these leading producers:
- GlaxoSmithKline (GSK)
- Sanofi Pasteur
- Pfizer
- Merck
- Novartis.
- Baxter BioPharma Solutions
- Boehringer Ingelheim
- Catalent
- Charles River Laboratories
- IDT Biologika GmbH
- Lonza
- Meridian Life Science
- SAFC (Sigma-Aldrich Fine Chemicals)
- SynCo Bio Partners.
Eight ways Vaccine Manufacturing Technology and Services: World Market 2013-2023 helps
In particular, then, our investigation gives you the following knowledge:
- Revenues to 2023 for the overall world market and 5 submarkets - you discover the industry's future prospects
- Market forecasting to 2023 for US, Japan, Germany, France, UK, Spain, Italy, Brazil, Russia, India and China - you see national sales predictions
- Profiles of 14 leading companies - you hear about activities, recent results, strategies and outlooks
- Predictions for outsourcing vaccine production - you assess developments and prospects for service providers (CMOs) and their clients
- Opinions on the sector - you read our interviews with authorities in the field
- Competition and opportunities influencing sales - you see what affects the future
- Discussions of what stimulates and restrains the industry and market - you explore business trends, drivers and restraints
- Prospects for established firms and those seeking to enter the sector - you assess needs, practices and outlooks for success.
That work gives independent analysis. You receive business intelligence found only in our report, seeing where financial prospects are good.
With our study you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses and decisions, saving time and getting you recognition for insight.
Ordering now lets you discover commercial prospects to 2023
Visiongain's investigation is for everyone needing forward-looking analysis of the vaccines industry and market. You find data, trends and predictions. Please order our report now.
1. EXECUTIVE SUMMARY
1.1 Overview
1.2 Review of the Vaccine Manufacturing Technology and Services Market
1.3 Aims, Scope and Format of Report
1.4 Research and Analysis Methods
2. INTRODUCTION TO VACCINES
2.1 The History of Vaccines
2.2 How do Vaccines Work?
2.2.1 Artificial Immunity
2.3 Types of Vaccine
2.3.1 Live, Attenuated Vaccines
2.3.2 Recombinant Live Vaccines
2.3.3 Inactivated Vaccines
2.3.4 Toxoid Vaccines
2.3.5 Subunit Vaccines
2.3.6 Conjugate Vaccines
2.3.7 Recombinant Subunit Vaccines
2.3.8 DNA Vaccines
2.3.9 Recombinant Vector Vaccines
2.3.10 Therapeutic Vaccines
2.4 Diseases Preventable with Vaccines
2.5 The Rise of the Vaccines Market
2.6 Technological and Regulatory Improvements
3. VACCINE MANUFACTURING TECHNOLOGIES, 2013
3.1 Summary of Vaccine Technology Trends
3.2 New Substrates for Vaccine Production
3.2.1 Shift towards Cell-Based Manufacturing Technology
3.2.2 Benefits of Cell-Based Techniques
3.2.3 Mammalian Cell Lines
3.2.3.1 MCDK (Madin Darby Canine Kidney Cells)
3.2.3.2 Vero Cells
3.2.3.3 PerC6 Cells
3.2.4 Avian-Derived Cell Lines
3.2.4.1 EB66 Stem Cell Technology: Vivalis
3.2.5 Plant-Based Vaccines
3.2.5.1 Medicago's Proficia VLP Vaccine Technology
3.2.6 Insect Egg-Based Production Systems
3.2.6.1 Novavax
3.2.6.2 Protein Sciences Corporation (PSC)
3.3 Next-Generation Expression Systems and Vectors: Increasing Production Yield
3.3.1 AdVac Technology: Crucell
3.3.2 AdCEV Vectors: AfriVax
3.3.3 Pfenex Expression Technology: Pfenex
3.4 Equipment Trends
3.4.1 The Shift Towards Disposable Single-use Equipment
3.4.2 Bioreactors and Vaccine Production
3.4.2.1 Single-Use Bioreactors
3.4.2.2 Main Applications of Disposable Bioreactors
3.4.2.3 Current Single-Use Bioreactor Systems on the Market
3.5 Prefilled Syringes and Vaccines
3.5.1 Growing Market for Pre-Filled Syringes
3.5.2 Leading Pre-Filled Vaccine Products 2012
3.5.3 Drivers and Restraints for Pre-filled Syringes
3.5.4 Product Stability and Quality Assurance Programme
3.5.4.1 Paediatric H1N1 Vaccine
3.5.4.2 Reported Challenges with Some Flu Vaccine
3.5.4.3 Reported Shelf Life Issues of Some H1N1 Vaccine
3.6 Lyophilisation and Vaccine Manufacturing
3.6.1 Lyophilisation of Vaccines will Increase
3.6.2 Commercial Drivers of Lyophilisation
3.6.3 Commercial Restraints for the Lyophilisation Technology Market
3.6.3.1 High Entry Barriers to Sector
3.7 Cell Media Can Improve Virus Yield
4. THE GLOBAL VACCINE MANUFACTURING MARKET 2013-2023
4.1 Overview of the Global Vaccine Manufacturing Market 2013-2023
4.2 World Vaccine Market Forecast 2013-2023
4.3 Growth in Vaccine Market Will Drive Efficiency in Vaccine Manufacturing
4.4 Paediatric Vaccines Market Overview
4.4.1 Paediatric Vaccines Market Forecast 2013-2023
4.5 Adult Prophylactic Vaccines Market Overview
4.5.1 Adult Prophylactic Vaccines Market Forecast 2013-2023
4.6 Influenza Vaccines Market Overview
4.6.1 Influenza Vaccines Market Forecast 2013-2023
4.7 Therapeutic Vaccines Market Overview
4.7.1 Therapeutic Vaccines Market Forecast 2013-2023
4.8 Leading Companies in the Vaccine Manufacturing Market 2012
4.8.1 GlaxoSmithKline
4.8.2 Sanofi Pasteur
4.8.3 Pfizer
4.8.4 Merck
4.8.5 Novartis
4.8.6 Other Vaccine Manufacturers
5. OUTSOURCING VACCINE MANUFACTURING 2013-2023
5.1 Outsourcing in the Pharmaceutical and Biotechnology Industry
5.1.1 Reasons to Outsource
5.1.2 Benefits of Outsourcing
5.1.3 The Challenges in Outsourcing Vaccine Manufacturing
5.1.4 Why Should Companies Outsource Vaccine Manufacturing?
5.1.5 Strategic Outsourcing vs. Tactical Outsourcing
5.1.6 Virtual Companies
5.2 Contract Manufacturing Organisations (CMOs)
5.2.1 Manufacturing Services Offered by CMOs
5.2.2 Vaccine Manufacturing Activities Typically Outsourced
5.3 The Pharmaceutical Contract Manufacturing Market: Overall Revenue Forecast 2013-2023
5.4 Contract Manufacturing Market for Vaccines 2013-2023
5.4.1 Market Size for Contract Manufacturing of Vaccines 2011
5.4.2 Vaccine Contract Manufacturing Market Forecast 2013-2023
5.5 Leading Vaccine Contract Manufacturing Organisations
5.5.1 Baxter BioPharma Solutions
5.5.2 Boehringer Ingelheim
5.5.2.1 Recent Financial Performance
5.5.2.2 Ben Venue Laboratories
5.5.2.3 Manufacturing Deals 2011-2012
5.5.2.4 Outlook
5.5.3 Catalent
5.5.3.1 Recent Financial Performance
5.5.3.2 Strong Growth for Oral Delivery Technologies
5.5.3.3 Catalent Injectable Vaccines
5.5.3.4 Catalent Adjusts its Services
5.5.3.5 Outlook
5.5.4 Charles River Laboratories
5.5.4.1 Revenue Analysis 2006-2011
5.5.4.2 Vaccine Manufacturing Services
5.5.4.3 Charles River Avian Vaccine Services
5.5.4.4 Outlook and Early Stage Restructuring
5.5.5 IDT Biologika GmbH
5.5.6 Lonza
5.5.6.1 Recent Financial Performance
5.5.6.2 Lonza: Biologics and Vaccines
5.5.6.3 Outlook
5.5.7 Meridian Life Science
5.5.7.1Revenue Analysis
5.5.8 SAFC (Sigma-Aldrich Fine Chemicals)
5.5.8.1 SAFC Revenue Analysis
5.5.9 SynCo Bio Partners
6. LEADING NATIONAL MARKETS 2013-2023
6.1 The US, Europe and Japan are the Largest Markets for Vaccines
6.2 The US Vaccine Market Forecast 2013-2023
6.2.1 The US National Vaccination Plan
6.2.2 Challenges in the US Vaccines Market
6.2.3 CMO Services in the US
6.3 The EU5 Vaccine Market Forecast 2013-2023
6.3.1 The EU5: Trends in CMO Services for Vaccine Manufacturing
6.3.2 The German Vaccine Market Forecast 2013-2023
6.3.3 The French Vaccine Market Forecast 2013-2023
6.3.4 The UK Vaccine Market Forecast 2013-2023
6.3.5 The Spanish Vaccine Market Forecast 2013-2023
6.3.6 The Italian Vaccine Market Forecast 2013-2023
6.4 The Japanese Vaccine Market
6.4.1 The Japanese Vaccine Market Forecast 2013-2023
6.4.2 CMOs in Japan
6.5 BRIC Nations: Market Overview
6.5.1 BRIC Nations: Vaccines Market Forecast 2013-2023
6.5.2 The Brazilian Vaccine Market Forecast 2013-2023
6.5.3 The Russian Vaccine Market Forecast 2013-2023
6.5.4 The Indian Vaccine Market Forecast 2013-2023
6.5.5 The Chinese Vaccine Market Forecast 2013-2023
7. VACCINE MANUFACTURING MARKET: WORLD MARKET TRENDS 2013-2023
7.1 SWOT Analysis of the Market 2013-2023
7.2 The Strengths of the Global Vaccine Manufacturing Market
7.2.1 Vaccines are a Healthcare Success
7.2.2 Blockbuster Vaccines
7.2.3 Low Generic Competition
7.3 Weaknesses of the Global Vaccine Manufacturing Market
7.3.1 Entry Barriers are High
7.3.2 Unpredictable Demand for Vaccines
7.3.3 High Costs and Complex Manufacturing Processes
7.3.4 Limitations of the Production Facility: Difficult Product Changeover
7.4 Opportunities for Vaccine Manufacturers
7.4.1 Vaccine Manufacturers Expand into New Indications
7.4.2 Bioterrorism
7.4.3 Pandemic Preparedness
7.4.4 Outsourcing Vaccine Manufacturing
7.4.5 Changing World Demographics
7.5 Threats in the Vaccine Manufacturing Market
7.5.1 Storage and Supply Difficulties for Vaccine Distribution Networks
7.5.2 Threat to Vaccine Prices
7.5.3 Consolidation of Vaccine Manufacturers
7.6 STEP Analysis: Vaccine Manufacturing Market 2013-2023
7.6.1 Social
7.6.1.1 The Controversy Surrounding Vaccines
7.6.1.2 Lack of Public Education Regarding Vaccines
7.6.2 Technological
7.6.2.1 New Types of Vaccines
7.6.2.2 Personalised Vaccines
7.6.2.3 New Adjuvants for Vaccines
7.6.2.4 New Vaccine Delivery Mechanisms and Formulations
7.6.3 Economic
7.6.3.1 Growth of the Emerging Economies
7.6.4 Political
7.6.4.1 Vaccines in National and International Policy
7.6.4.2 Government Preparedness and Protection
8. OPINIONS FROM OUR SURVEY
8.1 Interview with Richard van Rijnsoever, Director, Business Development, SynCo Bio Partners
8.1.1 Thoughts on Contract Manufacturing for Vaccines
8.1.2 Vaccine Services and Their Benefits
8.1.3 Impact of New Technology on Vaccine Manufacturing
8.1.4 Trends in Emerging Markets
8.2 Interview with Dr Louis Picker, Associate Director of OHSU's Vaccine and Gene Therapy Institute
8.2.1 The Basic Challenge of Developing a HIV Vaccine
8.2.2 Early Interception of HIV Infections via Antibodies
8.2.3 Early Interception of HIV Infections via T-Cells
8.2.4 The Use of CMV as a Vaccine Vector
8.2.5 The Effectiveness of the Vaccine in Humans
8.2.6 The Pre-Exposure Prophylactic Use of Anti-Retroviral Drugs as an Alternative Strategy
8.2.7 The Timeline for a Human Trial of the Vaccine
9. CONCLUSIONS
9.1 Vaccines Market Will Continue to Expand
9.2 Paediatric Vaccines Sector will Continue to Dominate
9.3 The Emerging Markets Gain Importance
9.4 Technology Drives Changes in Manufacturing
9.5 Outsourcing Vaccine Manufacturing Will Increase
1.1 Overview
1.2 Review of the Vaccine Manufacturing Technology and Services Market
1.3 Aims, Scope and Format of Report
1.4 Research and Analysis Methods
2. INTRODUCTION TO VACCINES
2.1 The History of Vaccines
2.2 How do Vaccines Work?
2.2.1 Artificial Immunity
2.3 Types of Vaccine
2.3.1 Live, Attenuated Vaccines
2.3.2 Recombinant Live Vaccines
2.3.3 Inactivated Vaccines
2.3.4 Toxoid Vaccines
2.3.5 Subunit Vaccines
2.3.6 Conjugate Vaccines
2.3.7 Recombinant Subunit Vaccines
2.3.8 DNA Vaccines
2.3.9 Recombinant Vector Vaccines
2.3.10 Therapeutic Vaccines
2.4 Diseases Preventable with Vaccines
2.5 The Rise of the Vaccines Market
2.6 Technological and Regulatory Improvements
3. VACCINE MANUFACTURING TECHNOLOGIES, 2013
3.1 Summary of Vaccine Technology Trends
3.2 New Substrates for Vaccine Production
3.2.1 Shift towards Cell-Based Manufacturing Technology
3.2.2 Benefits of Cell-Based Techniques
3.2.3 Mammalian Cell Lines
3.2.3.1 MCDK (Madin Darby Canine Kidney Cells)
3.2.3.2 Vero Cells
3.2.3.3 PerC6 Cells
3.2.4 Avian-Derived Cell Lines
3.2.4.1 EB66 Stem Cell Technology: Vivalis
3.2.5 Plant-Based Vaccines
3.2.5.1 Medicago's Proficia VLP Vaccine Technology
3.2.6 Insect Egg-Based Production Systems
3.2.6.1 Novavax
3.2.6.2 Protein Sciences Corporation (PSC)
3.3 Next-Generation Expression Systems and Vectors: Increasing Production Yield
3.3.1 AdVac Technology: Crucell
3.3.2 AdCEV Vectors: AfriVax
3.3.3 Pfenex Expression Technology: Pfenex
3.4 Equipment Trends
3.4.1 The Shift Towards Disposable Single-use Equipment
3.4.2 Bioreactors and Vaccine Production
3.4.2.1 Single-Use Bioreactors
3.4.2.2 Main Applications of Disposable Bioreactors
3.4.2.3 Current Single-Use Bioreactor Systems on the Market
3.5 Prefilled Syringes and Vaccines
3.5.1 Growing Market for Pre-Filled Syringes
3.5.2 Leading Pre-Filled Vaccine Products 2012
3.5.3 Drivers and Restraints for Pre-filled Syringes
3.5.4 Product Stability and Quality Assurance Programme
3.5.4.1 Paediatric H1N1 Vaccine
3.5.4.2 Reported Challenges with Some Flu Vaccine
3.5.4.3 Reported Shelf Life Issues of Some H1N1 Vaccine
3.6 Lyophilisation and Vaccine Manufacturing
3.6.1 Lyophilisation of Vaccines will Increase
3.6.2 Commercial Drivers of Lyophilisation
3.6.3 Commercial Restraints for the Lyophilisation Technology Market
3.6.3.1 High Entry Barriers to Sector
3.7 Cell Media Can Improve Virus Yield
4. THE GLOBAL VACCINE MANUFACTURING MARKET 2013-2023
4.1 Overview of the Global Vaccine Manufacturing Market 2013-2023
4.2 World Vaccine Market Forecast 2013-2023
4.3 Growth in Vaccine Market Will Drive Efficiency in Vaccine Manufacturing
4.4 Paediatric Vaccines Market Overview
4.4.1 Paediatric Vaccines Market Forecast 2013-2023
4.5 Adult Prophylactic Vaccines Market Overview
4.5.1 Adult Prophylactic Vaccines Market Forecast 2013-2023
4.6 Influenza Vaccines Market Overview
4.6.1 Influenza Vaccines Market Forecast 2013-2023
4.7 Therapeutic Vaccines Market Overview
4.7.1 Therapeutic Vaccines Market Forecast 2013-2023
4.8 Leading Companies in the Vaccine Manufacturing Market 2012
4.8.1 GlaxoSmithKline
4.8.2 Sanofi Pasteur
4.8.3 Pfizer
4.8.4 Merck
4.8.5 Novartis
4.8.6 Other Vaccine Manufacturers
5. OUTSOURCING VACCINE MANUFACTURING 2013-2023
5.1 Outsourcing in the Pharmaceutical and Biotechnology Industry
5.1.1 Reasons to Outsource
5.1.2 Benefits of Outsourcing
5.1.3 The Challenges in Outsourcing Vaccine Manufacturing
5.1.4 Why Should Companies Outsource Vaccine Manufacturing?
5.1.5 Strategic Outsourcing vs. Tactical Outsourcing
5.1.6 Virtual Companies
5.2 Contract Manufacturing Organisations (CMOs)
5.2.1 Manufacturing Services Offered by CMOs
5.2.2 Vaccine Manufacturing Activities Typically Outsourced
5.3 The Pharmaceutical Contract Manufacturing Market: Overall Revenue Forecast 2013-2023
5.4 Contract Manufacturing Market for Vaccines 2013-2023
5.4.1 Market Size for Contract Manufacturing of Vaccines 2011
5.4.2 Vaccine Contract Manufacturing Market Forecast 2013-2023
5.5 Leading Vaccine Contract Manufacturing Organisations
5.5.1 Baxter BioPharma Solutions
5.5.2 Boehringer Ingelheim
5.5.2.1 Recent Financial Performance
5.5.2.2 Ben Venue Laboratories
5.5.2.3 Manufacturing Deals 2011-2012
5.5.2.4 Outlook
5.5.3 Catalent
5.5.3.1 Recent Financial Performance
5.5.3.2 Strong Growth for Oral Delivery Technologies
5.5.3.3 Catalent Injectable Vaccines
5.5.3.4 Catalent Adjusts its Services
5.5.3.5 Outlook
5.5.4 Charles River Laboratories
5.5.4.1 Revenue Analysis 2006-2011
5.5.4.2 Vaccine Manufacturing Services
5.5.4.3 Charles River Avian Vaccine Services
5.5.4.4 Outlook and Early Stage Restructuring
5.5.5 IDT Biologika GmbH
5.5.6 Lonza
5.5.6.1 Recent Financial Performance
5.5.6.2 Lonza: Biologics and Vaccines
5.5.6.3 Outlook
5.5.7 Meridian Life Science
5.5.7.1Revenue Analysis
5.5.8 SAFC (Sigma-Aldrich Fine Chemicals)
5.5.8.1 SAFC Revenue Analysis
5.5.9 SynCo Bio Partners
6. LEADING NATIONAL MARKETS 2013-2023
6.1 The US, Europe and Japan are the Largest Markets for Vaccines
6.2 The US Vaccine Market Forecast 2013-2023
6.2.1 The US National Vaccination Plan
6.2.2 Challenges in the US Vaccines Market
6.2.3 CMO Services in the US
6.3 The EU5 Vaccine Market Forecast 2013-2023
6.3.1 The EU5: Trends in CMO Services for Vaccine Manufacturing
6.3.2 The German Vaccine Market Forecast 2013-2023
6.3.3 The French Vaccine Market Forecast 2013-2023
6.3.4 The UK Vaccine Market Forecast 2013-2023
6.3.5 The Spanish Vaccine Market Forecast 2013-2023
6.3.6 The Italian Vaccine Market Forecast 2013-2023
6.4 The Japanese Vaccine Market
6.4.1 The Japanese Vaccine Market Forecast 2013-2023
6.4.2 CMOs in Japan
6.5 BRIC Nations: Market Overview
6.5.1 BRIC Nations: Vaccines Market Forecast 2013-2023
6.5.2 The Brazilian Vaccine Market Forecast 2013-2023
6.5.3 The Russian Vaccine Market Forecast 2013-2023
6.5.4 The Indian Vaccine Market Forecast 2013-2023
6.5.5 The Chinese Vaccine Market Forecast 2013-2023
7. VACCINE MANUFACTURING MARKET: WORLD MARKET TRENDS 2013-2023
7.1 SWOT Analysis of the Market 2013-2023
7.2 The Strengths of the Global Vaccine Manufacturing Market
7.2.1 Vaccines are a Healthcare Success
7.2.2 Blockbuster Vaccines
7.2.3 Low Generic Competition
7.3 Weaknesses of the Global Vaccine Manufacturing Market
7.3.1 Entry Barriers are High
7.3.2 Unpredictable Demand for Vaccines
7.3.3 High Costs and Complex Manufacturing Processes
7.3.4 Limitations of the Production Facility: Difficult Product Changeover
7.4 Opportunities for Vaccine Manufacturers
7.4.1 Vaccine Manufacturers Expand into New Indications
7.4.2 Bioterrorism
7.4.3 Pandemic Preparedness
7.4.4 Outsourcing Vaccine Manufacturing
7.4.5 Changing World Demographics
7.5 Threats in the Vaccine Manufacturing Market
7.5.1 Storage and Supply Difficulties for Vaccine Distribution Networks
7.5.2 Threat to Vaccine Prices
7.5.3 Consolidation of Vaccine Manufacturers
7.6 STEP Analysis: Vaccine Manufacturing Market 2013-2023
7.6.1 Social
7.6.1.1 The Controversy Surrounding Vaccines
7.6.1.2 Lack of Public Education Regarding Vaccines
7.6.2 Technological
7.6.2.1 New Types of Vaccines
7.6.2.2 Personalised Vaccines
7.6.2.3 New Adjuvants for Vaccines
7.6.2.4 New Vaccine Delivery Mechanisms and Formulations
7.6.3 Economic
7.6.3.1 Growth of the Emerging Economies
7.6.4 Political
7.6.4.1 Vaccines in National and International Policy
7.6.4.2 Government Preparedness and Protection
8. OPINIONS FROM OUR SURVEY
8.1 Interview with Richard van Rijnsoever, Director, Business Development, SynCo Bio Partners
8.1.1 Thoughts on Contract Manufacturing for Vaccines
8.1.2 Vaccine Services and Their Benefits
8.1.3 Impact of New Technology on Vaccine Manufacturing
8.1.4 Trends in Emerging Markets
8.2 Interview with Dr Louis Picker, Associate Director of OHSU's Vaccine and Gene Therapy Institute
8.2.1 The Basic Challenge of Developing a HIV Vaccine
8.2.2 Early Interception of HIV Infections via Antibodies
8.2.3 Early Interception of HIV Infections via T-Cells
8.2.4 The Use of CMV as a Vaccine Vector
8.2.5 The Effectiveness of the Vaccine in Humans
8.2.6 The Pre-Exposure Prophylactic Use of Anti-Retroviral Drugs as an Alternative Strategy
8.2.7 The Timeline for a Human Trial of the Vaccine
9. CONCLUSIONS
9.1 Vaccines Market Will Continue to Expand
9.2 Paediatric Vaccines Sector will Continue to Dominate
9.3 The Emerging Markets Gain Importance
9.4 Technology Drives Changes in Manufacturing
9.5 Outsourcing Vaccine Manufacturing Will Increase
LIST OF TABLES
Table 1.1 Currency Exchange Rates, 2011
Table 2.1 Timeline of Key Events in Vaccine Development, c.1000 AD-Present
Table 3.1 Vaccine Development Pipeline using Protein Sciences Corporation's BEVS Vaccine Technology, 2012
Table 3.2 Vaccine Development Pipeline Using Crucell's AdVac Technology, 2012
Table 3.3 Benefits and Drawbacks of Using Disposable Technology for Vaccine Production, 2012
Table 3.4 Companies Providing Disposable Biomanufacturing Platforms/Systems, 2011
Table 3.5 Some Leading Pre-Filled Syringe Vaccine Products, 2012
Table 3.6 Prominent Lyophilised Vaccines, 2012
Table 3.7 Examples Serum-free Media for Vaccines Manufacturing, 2012
Table 4.1 Sectors within the Vaccines Market: Description, Sales ($bn), Market Shares (%), 2011
Table 4.2 Global Vaccine Manufacturing Revenue Forecasts - Overall Market and Submarkets ($bn), AGR (%), CAGR (%), 2011-2017
Table 4.3 Global Vaccine Manufacturing Revenue Forecasts - Overall Market and Submarkets ($bn), AGR (%), CAGR (%), 2017-2023
Table 4.4 Global Vaccine Manufacturing: World Market Shares by Region (%), 2011, 2017 & 2023
Table 4.5 Paediatric Vaccine Manufacturing Forecast ($bn), AGR (%), CAGR (%), 2011-2017
Table 4.6 Paediatric Vaccine Manufacturing Forecast ($bn), AGR (%), CAGR (%), 2017-2023
Table 4.7 Adult Prophylactic Vaccine Manufacturing Forecast ($bn), AGR (%), CAGR (%), 2011-2017
Table 4.8 Adult Prophylactic Vaccine Manufacturing Forecast ($bn), AGR (%), CAGR (%), 2017-2023
Table 4.9 Influenza Vaccine Manufacturing Forecast ($bn), AGR (%), CAGR (%), 2011-2017
Table 4.10 Influenza Vaccine Manufacturing Forecast ($bn), AGR (%), CAGR (%), 2017-2023
Table 4.11 Therapeutic Vaccine Manufacturing Forecast ($bn), AGR (%), CAGR (%), 2011-2017
Table 4.12 Therapeutic Vaccine Manufacturing Forecast ($bn), AGR (%), CAGR (%), 2017-2023
Table 4.13 Leading Companies in the Vaccines Market: Revenues ($bn), Overall Market Shares (%), 2011
Table 5.1 Pharmaceutical Contract Manufacturing Market: Overall Revenue Forecast, ($bn), AGR (%), CAGR (%), 2011-2017
Table 5.2 Pharmaceutical Contract Manufacturing Market: Overall Revenue Forecast, ($bn), AGR (%), CAGR (%), 2017-2023
Table 5.3 Vaccine Contract Manufacturing Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 5.4 Vaccine Contract Manufacturing Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 5.5 Prominent Vaccine Contract Manufacturing Organisations, 2012
Table 5.6 Baxter BioPharma Solutions Capabilities, 2012
Table 5.7 Boehringer Ingelheim: Contract Manufacturing Revenue ($bn) by Division, 2009-2011
Table 5.8 Catalent: Revenue ($bn) by Division, 2009-2011
Table 5.9 Selected Services Provided by Charles River Laboratories, 2012
Table 5.10 Charles River Laboratories Revenue ($bn), 2006-2011
Table 5.11 Charles River Laboratories Revenue ($bn) by Business Segment, 2009-2011
Table 5.12 Charles River Laboratories: cGMP Vaccine Manufacturing and Testing Capabilities, 2012
Table 5.13 Lonza: Custom Manufacturing Revenue ($bn), 2009-2011
Table 5.14 Meridian Bioscience & Meridian Life Science: Revenue ($m), 2009-2012
Table 5.15 SAFC Revenue ($m), AGR (%), 2007-2011
Table 5.16 SynCo Bio Partners Capabilities, 2012
Table 6.1 Leading National Vaccine Manufacturing Technology and Services Revenue Forecasts ($bn), AGR (%), CAGR (%), 2011-2017
Table 6.2 Leading National Vaccine Manufacturing Technology and Services Revenue Forecasts ($bn), AGR (%), CAGR (%), 2017-2023
Table 6.3 Vaccine Manufacturing Technology and Services: World Market Shares by Region (%), 2011, 2017 & 2023
Table 6.4 The US Drug Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2011-2017
Table 6.5 The US Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2017-2023
Table 6.6 EU5 Vaccine Manufacturing Technology and Services Forecasts ($bn), AGR (%), CAGR (%), 2011-2017
Table 6.7 EU5 Vaccine Manufacturing Technology and Services Forecasts ($bn), AGR (%), CAGR (%), 2017-2023
Table 6.8 Vaccine Manufacturing Technology and Services: EU5 Market Shares by Region (%), 2011, 2017 & 2023
Table 6.9 The German Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2011-2017
Table 6.10 The German Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2017-2023
Table 6.11 The French Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2011-2017
Table 6.12 The French Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2017-2023
Table 6.13 The UK Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2011-2017
Table 6.14 The UK Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2017-2023
Table 6.15 The Spanish Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2011-2017
Table 6.16 The Spanish Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2017-2023
Table 6.17 The Italian Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2011-2017
Table 6.18 The Italian Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2017-2023
Table 6.19 The Japanese Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2011-2017
Table 6.20 The Japanese Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2017-2023
Table 6.21 BRIC Nations: Vaccine Manufacturing Technology and Services Forecasts ($bn), AGR (%), CAGR (%), 2011-2017
Table 6.22 BRIC Nations: Vaccine Manufacturing Technology and Services Forecasts ($bn), AGR (%), CAGR (%), 2017-2023
Table 6.23 Vaccine Manufacturing Technology and Services: BRIC Market Shares by Region (%), 2011, 2017 & 2023
Table 6.24 The Brazilian Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2011-2017
Table 6.25 The Brazilian Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2017-2023
Table 6.26 The Russian Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2011-2017
Table 6.27 The Russian Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2017-2023
Table 6.28 The Indian Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2011-2017
Table 6.29 The Indian Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2017-2023
Table 6.30 The Chinese Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2011-2017
Table 6.31 The Chinese Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2017-2023
Table 7.1 SWOT Analysis for the Global Vaccine Manufacturing Sector, 2013-2023
Table 1.1 Currency Exchange Rates, 2011
Table 2.1 Timeline of Key Events in Vaccine Development, c.1000 AD-Present
Table 3.1 Vaccine Development Pipeline using Protein Sciences Corporation's BEVS Vaccine Technology, 2012
Table 3.2 Vaccine Development Pipeline Using Crucell's AdVac Technology, 2012
Table 3.3 Benefits and Drawbacks of Using Disposable Technology for Vaccine Production, 2012
Table 3.4 Companies Providing Disposable Biomanufacturing Platforms/Systems, 2011
Table 3.5 Some Leading Pre-Filled Syringe Vaccine Products, 2012
Table 3.6 Prominent Lyophilised Vaccines, 2012
Table 3.7 Examples Serum-free Media for Vaccines Manufacturing, 2012
Table 4.1 Sectors within the Vaccines Market: Description, Sales ($bn), Market Shares (%), 2011
Table 4.2 Global Vaccine Manufacturing Revenue Forecasts - Overall Market and Submarkets ($bn), AGR (%), CAGR (%), 2011-2017
Table 4.3 Global Vaccine Manufacturing Revenue Forecasts - Overall Market and Submarkets ($bn), AGR (%), CAGR (%), 2017-2023
Table 4.4 Global Vaccine Manufacturing: World Market Shares by Region (%), 2011, 2017 & 2023
Table 4.5 Paediatric Vaccine Manufacturing Forecast ($bn), AGR (%), CAGR (%), 2011-2017
Table 4.6 Paediatric Vaccine Manufacturing Forecast ($bn), AGR (%), CAGR (%), 2017-2023
Table 4.7 Adult Prophylactic Vaccine Manufacturing Forecast ($bn), AGR (%), CAGR (%), 2011-2017
Table 4.8 Adult Prophylactic Vaccine Manufacturing Forecast ($bn), AGR (%), CAGR (%), 2017-2023
Table 4.9 Influenza Vaccine Manufacturing Forecast ($bn), AGR (%), CAGR (%), 2011-2017
Table 4.10 Influenza Vaccine Manufacturing Forecast ($bn), AGR (%), CAGR (%), 2017-2023
Table 4.11 Therapeutic Vaccine Manufacturing Forecast ($bn), AGR (%), CAGR (%), 2011-2017
Table 4.12 Therapeutic Vaccine Manufacturing Forecast ($bn), AGR (%), CAGR (%), 2017-2023
Table 4.13 Leading Companies in the Vaccines Market: Revenues ($bn), Overall Market Shares (%), 2011
Table 5.1 Pharmaceutical Contract Manufacturing Market: Overall Revenue Forecast, ($bn), AGR (%), CAGR (%), 2011-2017
Table 5.2 Pharmaceutical Contract Manufacturing Market: Overall Revenue Forecast, ($bn), AGR (%), CAGR (%), 2017-2023
Table 5.3 Vaccine Contract Manufacturing Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 5.4 Vaccine Contract Manufacturing Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 5.5 Prominent Vaccine Contract Manufacturing Organisations, 2012
Table 5.6 Baxter BioPharma Solutions Capabilities, 2012
Table 5.7 Boehringer Ingelheim: Contract Manufacturing Revenue ($bn) by Division, 2009-2011
Table 5.8 Catalent: Revenue ($bn) by Division, 2009-2011
Table 5.9 Selected Services Provided by Charles River Laboratories, 2012
Table 5.10 Charles River Laboratories Revenue ($bn), 2006-2011
Table 5.11 Charles River Laboratories Revenue ($bn) by Business Segment, 2009-2011
Table 5.12 Charles River Laboratories: cGMP Vaccine Manufacturing and Testing Capabilities, 2012
Table 5.13 Lonza: Custom Manufacturing Revenue ($bn), 2009-2011
Table 5.14 Meridian Bioscience & Meridian Life Science: Revenue ($m), 2009-2012
Table 5.15 SAFC Revenue ($m), AGR (%), 2007-2011
Table 5.16 SynCo Bio Partners Capabilities, 2012
Table 6.1 Leading National Vaccine Manufacturing Technology and Services Revenue Forecasts ($bn), AGR (%), CAGR (%), 2011-2017
Table 6.2 Leading National Vaccine Manufacturing Technology and Services Revenue Forecasts ($bn), AGR (%), CAGR (%), 2017-2023
Table 6.3 Vaccine Manufacturing Technology and Services: World Market Shares by Region (%), 2011, 2017 & 2023
Table 6.4 The US Drug Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2011-2017
Table 6.5 The US Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2017-2023
Table 6.6 EU5 Vaccine Manufacturing Technology and Services Forecasts ($bn), AGR (%), CAGR (%), 2011-2017
Table 6.7 EU5 Vaccine Manufacturing Technology and Services Forecasts ($bn), AGR (%), CAGR (%), 2017-2023
Table 6.8 Vaccine Manufacturing Technology and Services: EU5 Market Shares by Region (%), 2011, 2017 & 2023
Table 6.9 The German Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2011-2017
Table 6.10 The German Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2017-2023
Table 6.11 The French Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2011-2017
Table 6.12 The French Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2017-2023
Table 6.13 The UK Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2011-2017
Table 6.14 The UK Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2017-2023
Table 6.15 The Spanish Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2011-2017
Table 6.16 The Spanish Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2017-2023
Table 6.17 The Italian Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2011-2017
Table 6.18 The Italian Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2017-2023
Table 6.19 The Japanese Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2011-2017
Table 6.20 The Japanese Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2017-2023
Table 6.21 BRIC Nations: Vaccine Manufacturing Technology and Services Forecasts ($bn), AGR (%), CAGR (%), 2011-2017
Table 6.22 BRIC Nations: Vaccine Manufacturing Technology and Services Forecasts ($bn), AGR (%), CAGR (%), 2017-2023
Table 6.23 Vaccine Manufacturing Technology and Services: BRIC Market Shares by Region (%), 2011, 2017 & 2023
Table 6.24 The Brazilian Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2011-2017
Table 6.25 The Brazilian Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2017-2023
Table 6.26 The Russian Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2011-2017
Table 6.27 The Russian Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2017-2023
Table 6.28 The Indian Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2011-2017
Table 6.29 The Indian Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2017-2023
Table 6.30 The Chinese Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2011-2017
Table 6.31 The Chinese Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2017-2023
Table 7.1 SWOT Analysis for the Global Vaccine Manufacturing Sector, 2013-2023
The France Vaccine Market Forecast 2013-2023
A catch-up immunisation programme against HPV was instituted for all women under the age of 25 in 2009, with government health authorities giving official recommendation to Gardasil rather than Cervarix. France’s immunisation coverage rates are similar to those in the other EU major markets, except in the case of hepatitis B virus. Fears that this vaccine was linked to multiple sclerosis and other adverse events saw hepatitis B vaccination levels drop sharply from 1998 onwards. Ten years on, hepatitis B vaccination levels are around 40% in France, rather than 90%+ as in the other countries of industrialised Europe.
Like the other major European economies, France is looking to reduce healthcare spending in the face of economic pressures caused by the global financial situation since 2008. In 2012, the French government announced, as part of the austerity plan, the national target for expenditure in public healthcare has been reduced to a maximum 2.5% year-on-year spending growth, down from 2.8% year-on-year set in 2011. This is less radical than the cost-curtailment measures enacted in other European countries, but contributes to the overall downward pressure on the European pharmaceutical market. Visiongain believes that despite this restraint, the French vaccines market will record 9.4% CAGR for the forecast period of this report, reaching revenues of $6.3bn by 2023, and increasing its share of the EU market to 23.2%.
Like other European markets, the French contract manufacturing market has suffered in recent years as a result of the global financial crisis. Reports suggest that a number of contract manufacturers in the country have gone out of business as a result of project cancellations. Around half of pharmaceutical manufacturing for the French market is still performed in France, reports suggest. The French manufacturing outsourcing market is likely to see growth throughout the forecast period; this will primarily be driven by increased generalisation of the market, rather than increased activities for vaccine manufacturing.
The UK Vaccine Market Forecast 2013-2023
In 2012, the UK passed a bill for reforms to pharma healthcare pricing, with a move towards valuebased pricing. In the light of many companies downsizing operations in the UK, the government has reacted by introducing new tax cut incentives. This is to encourage high-value-added manufacturing by offering a reduced tax rate of 10% (instead of the general rate of 23%) on profits attributed to patents and similar types of intellectual property from April 2013. Visiongain expects that this will encourage pharmaceutical manufacturing activities in the UK, driving growth through the first half of the forecast period.
